Polyethylene glycol-drug ester conjugates for prolonged retention of small inhaled drugs in the lung

Journal of Controlled Release

Volumn 171, Issue 2, 2013, Pages 234-240

  Bayard, F J C ^a,e   Thielemans, W ^a   Pritchard, D I ^a   Paine, S W ^b   Young, S S ^c   Backman P ^d   Ewing, P ^d   Bosquillon, C ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ASTRAZENECA   (United Kingdom)

^d ASTRAZENECA R AND D   (Sweden)

^e Fujifilm Diosynth Biotechnologies   (United Kingdom)

Author keywords

Pharmacokinetic; Polyethylene glycol; Polymer conjugation; Pro drug; Pulmonary delivery

Indexed keywords

ESTERS; MOTION PICTURE EXPERTS GROUP STANDARDS; PHARMACOKINETICS; POLYETHYLENE GLYCOLS; POLYETHYLENES;

LACTATE DEHYDROGENASE; NEBULISATION; NOVEL STRATEGIES; PREDNISOLONE; PRO-DRUG; PULMONARY DELIVERY; PULMONARY TISSUES; RESIDENCE TIME;

DRUG INTERACTIONS;

BUFFER; ESTER DERIVATIVE; LACTATE DEHYDROGENASE; MACROGOL; PREDNISOLONE;

ARTICLE; CONCENTRATION (PARAMETERS); CONJUGATE; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RETENTION; HUMAN; HUMAN CELL; HYDROLYSIS; LUNG; LUNG PERFUSION; PH; PRIORITY JOURNAL;

PHARMACOKINETIC; POLYETHYLENE GLYCOL; POLYMER CONJUGATION; PRO-DRUG; PULMONARY DELIVERY;

ADMINISTRATION, INHALATION; ANIMALS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; ESTERS; HUMANS; LUNG; MALE; MODELS, BIOLOGICAL; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; PREDNISOLONE; RATS; RATS, WISTAR;

EID: 84882421342     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.07.023     Document Type: Article

References (37)

1. J.S. Patton, P.R. Byron, Inhaling medicines: delivering drugs to the body through the lungs, Nat. Rev. Drug Discov. 6 (2007) 67-74. (Pubitemid 46020287)
2. A.E. Cooper, D. Ferguson, K. Grime, Optimisation of DMPK by the inhaled route: challenges and approaches, Curr. Drug Metab. 13 (2012) 457-473.
3. H.W. Kelly, Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids, J. Allergy Clin. Immunol. 102 (1998) S36-S51.
4. C.A. Sorkness, Establishing a therapeutic index for the inhaled corticosteroids: Part II-Comparisons of systemic activity and safety among different inhaled corticosteroids, J. Allergy Clin. Immunol. 102 (1998) S52-S64.
5. P. Hogger, Dose response and therapeutic index of inhaled corticosteroids in asthma, Curr. Opin. Pulm. Med. 9 (2003) 1-8. (Pubitemid 35440963)
6. J. Rosenborg, P. Larsson, Z. Rott, C. Böcskei, M. Poczi, G. Juhász, Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients, Respir. Med. 96 (2002) 412-417.
7. J.Z. Yang, A.L. Young, P.C. Chiang, A. Thurston, D.K. Pretzer, Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies, J. Pharm. Sci. 97 (2008) 4869-4878.
8. B. Forbes, B. Asgharian, L.A. Dailey, D. Ferguson, P. Gerde, M. Gumbleton, L. Gustavsson, C. Hardy, D. Hassall, R. Jones, R. Lock, J. Maas, T. McGovern, G.R. Pitcairn, G. Somers, R.K. Wolff, Challenges in inhaled product development and opportunities for open innovation, Adv. Drug Deliv. Rev. 63 (2011) 69-87.
9. X. Chen, W. Huang, B.C. Wong, L. Yin, Y.F. Wong, M. Xu, Z. Yang, Liposomes prolong the therapeutic effect of anti-asthmatic medication via pulmonary delivery, Int. J. Nanomedicine 7 (2012).
10. E. Rytting, M. Bur, R. Cartier, T. Bouyssou, X. Wang, M. Krüger, C.M. Lehr, T. Kissel, In vitro and in vivo performance of biocompatible negatively-charged salbutamol-loaded nanoparticles, J. Control. Release 141 (2010) 101-107.
11. Y.J. Oh, J. Lee, J.Y. Seo, T. Rhim, S.H. Kim, H.J. Yoon, K.Y. Lee, Preparation of budesonide-loaded porous PLGA microparticles and their therapeutic efficacy in a murine asthma model, J. Control. Release 150 (2011) 56-62.
12. E. Rytting, J. Nguyen, X. Wang, T. Kissel, Biodegradable polymeric nanocarriers for pulmonary drug delivery, Expert Opin. Drug Deliv. 5 (2008) 629-639. (Pubitemid 351998253)
13. M. Beck-Broichsitter, O.M. Merkel, T. Kissel, Controlled pulmonary drug and gene delivery using polymeric nano-carriers, J. Control. Release 161 (2012) 214-224.
14. A. Tronde, B. Nordén, A.B. Jeppsson, P. Brunmark, E. Nilsson, H. Lennernäs, U.H. Bengtsson, Drug absorption from the isolated perfused rat lung-correlations with drug physicochemical properties and epithelial permeability, J. Drug. Target. (2003) 61-74. (Pubitemid 36527397)
15. H. Gursahani, J. Riggs-Sauthier, J. Pfeiffer, D. Lechuga-Ballesteros, C.S. Fishburn, Absorption of polyethylene glycol (PEG) polymers: the effect of PEG size on permeability, J. Pharm. Sci. 98 (2009) 2847-2856.
16. E. Markovsky, H. Baabur-Cohen, A. Eldar-Boock, L. Omer, G. Tiram, S. Ferber, P. Ofek, D. Polyak, A. Scomparin, R. Satchi-Fainaro, Administration, distribution, metabolism and elimination of polymer therapeutics, J. Control. Release 161 (2012) 446-460.
17. G. Pasut, F.M. Veronese, State of the art in PEGylation: the great versatility achieved after forty years of research, J. Control. Release 161 (2012) 461-472.
18. Y.S. Youn, M.J. Kwon, D.H. Na, S.Y. Chae, S. Lee, K.C. Lee, Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: optimization by PEG size selection, J. Control. Release 125 (2008) 68-75. (Pubitemid 350198681)
19. H. Katsumi, M. Takashima, J. Sano, K. Nishiyama, N. Kitamura, T. Sakane, T. Hibi, A. Yamamoto, Development of polyethylene glycol-conjugated alendronate, a novel nitrogen-containing bisphosphonate derivative: evaluation of absorption, safety, and effects after intrapulmonary administration in rats, J. Pharm. Sci. 100 (2011) 3783-3792.
20. C.J. Morris, K. Beck, M.A. Fox, D. Ulaeto, G.C. Clark, M. Gumbleton, Pegylation of antimicrobial peptides maintains the active peptide conformation, model membrane interactions, and antimicrobial activity while improving lung tissue biocompatibility following airway delivery, Antimicrob. Agents Chemother. 56 (2012) 3298-3308.
21. X.-Q. Li, F.-T. Meng, H. Guang, Z.-G. Su, A simple and efficient method for synthesis of carboxymethylated polyethyleneglycol, J. Chem. Res. 2005 (2005) 280-281. (Pubitemid 40910793)
22. P. Gerde, P. Ewing, L. Låstbom, Å. Ryrfeldt, J. Waher, G. Lidén, A novel method to aerosolize powder for short inhalation exposures at high concentrations: isolated rat lungs exposed to respirable Diesel soot, Inhal. Toxicol. 16 (2004) 45-52. (Pubitemid 38101401)
23. J.C. Ojoo, S.A. Mulrennan, J.A. Kastelik, A.H. Morice, A.E. Redington, Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis, Thorax 60 (2005) 22-26. (Pubitemid 40101013)
24. J.F. Hunt, K.Z. Fang, R. Malik, A. Snyder, N. Malhotra, T.A.E. Platts-Mills, B. Gaston, Endogenous airway acidification - Implications for asthma pathophysiology, Am. J. Respir. Crit. Care Med. 161 (2000) 694-699. (Pubitemid 30171718)
25. R. Koczulla, S. Dragonieri, R. Schot, R. Bals, S.A. Gauw, C. Vogelmeier, K.F. Rabe, P.J. Sterk, P.S. Hiemstra, Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients, Respir. Res. 10 (2009).
26. B.M. Agoram, P.A. Milligan, P.H. van der Graaf, A non-parametric method to analyse time-course of effect in the absence of pharmacokinetic data: application to inhaled bronchodilators, Eur. J. Pharm. Sci. 34 (2008) 250-256.
27. T.V. Doan, N. Grégoire, I. Lamarche, P. Gobin, S. Marchand, W. Couet, J.C. Olivier, A preclinical pharmacokinetic modeling approach to the biopharmaceutical characterization of immediate and microsphere-based sustained release pulmonary formulations of rifampicin, Eur. J. Pharm. Sci. 48 (2013) 223-230.
28. M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery, Adv. Drug Deliv. Rev. 58 (2006) 1030-1060. (Pubitemid 44712023)
29. E. Selg, P. Ewing, F. Acevedo, C.O. Sjöberg, A. Ryrfeldt, P. Gerde, Dry powder inhalation exposures of the endotracheally intubated rat lung, ex vivo and in vivo: the pulmonary pharmacokinetics of fluticasone furoate, J. Aerosol Med. Pulm. Drug Deliv. 26 (2013) 181-189.
30. G.I. Somers, B.M. Lowdon, A.E. Jones, C. Freathy, S. Ho, A.J. Woodrooffe, M.K. Bayliss, G.R. Manchee, A comparison of the expression and metabolizing activities of phase I and II enzymes in freshly isolated human lung parenchymal cells and cryopreserved human hepatocytes, Drug Metab. Dispos. 35 (2007) 1797-1805. (Pubitemid 47481571)
31. B.M. Liederer, R.T. Borchardt, Enzymes involved in the bioconversion of ester-based prodrugs, J. Pharm. Sci. 95 (2006) 1177-1195. (Pubitemid 43874435)
32. A.E. Vickers, R.M. Jimenez, M.C. Spaans, V. Pflimlin, R.L. Fisher, K. Brendel, Human and rat lung biotransformation of cyclosporin A and its derivatives using slices and bronchial epithelial cells, Drug. Metab. Dispos. 25 (1997) 873-880. (Pubitemid 27318606)
33. R.B. Greenwald, A. Pendri, C.D. Conover, C. Lee, Y.H. Choe, C. Gilbert, A. Martinez, J. Xia, D. Wu, M.-m. Hsue, Camptothecin-20-PEG ester transport forms: the effect of spacer groups on antitumor activity, Bioorg. Med. Chem. 6 (1998) 551-562. (Pubitemid 28264077)
34. W. Wichitnithad, U. Nimmannit, P.S. Callery, P. Rojsitthisak, Effects of different carboxylic ester spacers on chemical stability, release characteristics, and anticancer activity of mono-PEGylated curcumin conjugates, J. Pharm. Sci. 100 (2011) 5206-5218.
35. Y. Huang, J. Lu, X. Gao, J. Li, W. Zhao, M. Sun, D.B. Stolz, R. Venkataramanan, L.C. Rohan, S. Li, PEG-derivatized embelin as a dual functional carrier for the delivery of paclitaxel, Bioconjug. Chem. 23 (2012) 1443-1451.
36. J.Z. Sun, P.R. Byron, F. Rypacek, Solute absorption from the airways of the isolated rat lung. V. Charge effects on the absorption of copolymers of N(2-hydroxyethyl)-DL-aspartamide with DL-aspartic acid or dimethylaminopropyl- DL-aspartamide, Pharm. Res. 16 (1999) 1104-1108. (Pubitemid 29368160)
37. D.R. Klonne, D.E. Dodd, P.E. Losco, C.M. Troup, T.R. Tyler, 2-week aerosol inhalation study on polyethylene glycol-(PEG)-3350 in F344 rats, Drug Chem. Toxicol. 12 (1989) 39-48. (Pubitemid 19093793)